Navigation Links
Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
Date:8/12/2008

Owing to Well-Established and Effective Insulin-Based Therapies, Market Growth Will be Modest Through 2017, According to a New Report from Decision

Resources

WALTHAM, Mass., Aug. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the most significant driver of growth in the type 1 diabetes market will be the shift in the standard of care away from regular human insulins and neutral protamine Hagedorn (NPH) insulin to more-expensive rapid-acting insulin analogues and long-acting insulin analogues. Short-acting insulin analogues provide a more rapid onset of action than regular human insulin and long-acting insulin analogues require fewer injections than NPH insulin.

The new Pharmacor report entitled Type 1 Diabetes finds that market growth will be driven by rapid-acting insulin analogues that include Novo Nordisk's Novorapid/Novolog and Eli Lilly's Humalog as well as long-acting insulin analogues that include Sanofi-Aventis's Lantus and Novo Nordisk's Levemir. Since the type 1 diabetes market is saturated with effective and well-established insulin-based therapies that have been in use for decades, the report forecasts only modest 1.2 percent annual market growth through 2017.

According to the report, novel devices designed to allow needle-free administration of insulin could revolutionize treatment of type 1 diabetes, but their uptake will be hampered by physicians' negative experience with Pfizer/Nektar's inhaled insulin, Exubera, which fared poorly in the market owing to safety concerns and its premium price. Among the insulin-based therapies currently in the pipeline for type 1 diabetes, oral and transdermal insulins hold the greatest promise but their use will be constrained by dosing variability issues that are likely to dissuade physicians from prescribing them.

The report also finds that novel immunomodulators, particularly Diamyd Medical's DiamydT and DeveloGen/Andromeda Biotech's DiaPep-277, will drive growth in the Type 1 diabetes market. Through 2017, sales of DiamydT and DiaPep-277 will reach $45 million.

"Experts that we interviewed unanimously agree that the treatment of type 1 diabetes is characterized by a high level of unmet need for therapies that can halt the destruction of insulin-producing pancreatic-beta cells," said Caroline Gates, analyst at Decision Resources. "Immunomodulators have the potential to preserve beta-cell function, but their use will be hampered by long-term safety concerns, high prices and by the small number of eligible patients who would benefit from these agents."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
2. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
3. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
4. Treatment Corrects Severe Insulin Imbalance in Animal Studies
5. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
6. Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
7. Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
8. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
9. Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin
10. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
11. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):